| Similar Articles |
|---|
 |
The Motley Fool
July 5, 2005
Alyce Lomax |
Business As Usual at Walgreen Walgreen's same-store sales for June certainly don't disappoint. Investors might question whether the retail pharmacy can keep up the great work.   |
The Motley Fool
July 29, 2011
Shubh Datta |
A Drug Retailer for Your Portfolio With a strong balance sheet, Walgreen looks like a good buy. |
The Motley Fool
October 4, 2005
Seth Jayson |
Same Old Same-Store Story Reports from Walgreen and Rite Aid confirm the obvious. Investors will nearly always do better buying the best company in any given space. |
The Motley Fool
March 28, 2005
Alyce Lomax |
A Cool Quarter for Walgreen Are second-quarter earnings putting a damper on Walgreen? |
The Motley Fool
March 22, 2004
Alyce Lomax |
Walgreen's Green Quarter Investors take an earnings miss to heart. But the future looks good. |
The Motley Fool
July 6, 2004
Alyce Lomax |
Not Ready for Rite Aid Can the drugstore chain hold a candle to the competition? Its shares are trading at 22 times forward earnings, making it a seemingly less-than-advantageous time to place a bet on them. |
The Motley Fool
January 3, 2005
Nathan Slaughter |
Walgreen Seeing Green Rivals CVS and Rite Aid have a bitter pill to swallow as Walgreen stays strong. While Walgreen's revenues were in line with forecasts, the stronger-than-expected bottom line has the stock gaining ground. |
The Motley Fool
October 8, 2011
Shubh Datta |
Impasse Hurts Walgreen's Quarter Walgreen posted a staggering 69% earnings jump but still saw its shares slide. |
The Motley Fool
June 10, 2004
Alyce Lomax |
Summer Starts at CVS The drugstore company releases same-store sales results on the cusp of its Eckerd acquisition. |
The Motley Fool
August 15, 2005
Bobby Shethia |
Walgreen's Prescription for Success The drugstore chain's smart and steady growth makes it a good choice for investors. |
The Motley Fool
January 3, 2006
Stephen D. Simpson |
Walgreen Reaps Rewards of Rx The nation's top pharmacy keeps on rolling, but investors might want to keep an eye on the new ventures. |
The Motley Fool
December 16, 2004
Nathan Slaughter |
Rx: Get Some Earnings Quick The No. 3 drug chain Rite Aid posts a sharp drop in earnings and slashes guidance again. |
The Motley Fool
January 4, 2005
Seth Jayson |
Rite Aid Still Needs First Aid Sales keep slacking for this tough turnaround. This doesn't mean investors should necessarily jump ship. |
The Motley Fool
January 5, 2004
Jeff Hwang |
Prescriptions Boost Walgreen Earnings and sales bumped by early flu season and improved non-pharmacy sales. |
The Motley Fool
September 27, 2005
Nathan Slaughter |
All Green for Walgreen The retail pharmacy posts record earnings and sales for the 31st consecutive year. Even though Walgreen's latest numbers came up a little short of the mark, it wasn't enough to capture the attention of value investors. |
The Motley Fool
October 6, 2010
Rich Smith |
This Just In: Upgrades and Downgrades Jefferies on Walgreen: Take two shares and thank me in the morning. |
The Motley Fool
March 23, 2011
Andrew Bond |
What More Can You Ask of Walgreen? A sell-off in shares of Walgreen provides a buying opportunity for investors who want in on a best-of-breed company at a discount. |
The Motley Fool
December 26, 2006
Matthew Crews |
Walgreen Represents This drugstore business has proven itself; does its stock match up? |
The Motley Fool
June 2, 2004
Alyce Lomax |
Walgreen's Mellow May Will the drugstore chain get a taste of its own medicine? |
The Motley Fool
February 4, 2005
Steven Mallas |
Walgreen's Wonderful Comps This drugstore chain doesn't need any medical attention. January comps prove it. |
The Motley Fool
January 7, 2010
Gerard Torres |
Walgreen Lives to Fight Another Day Despite recent success, Walgreen continues to face stiff competition. |
The Motley Fool
September 22, 2005
Stephen D. Simpson |
Rite Aid Not Right Yet The bleeding seems to have stopped at this pharmacy, but recovery could be a long and slow road. Intrepid, not to mention patient, investors may see potential here, but there are far better turnaround ideas to be had. |
The Motley Fool
March 9, 2004
Alyce Lomax |
February Frenzy at CVS, Rite Aid The flu season's early end hasn't stopped drugstore retailers. |
The Motley Fool
October 6, 2004
Steven Mallas |
Walgreen Getting Greener The retail pharmacy's comps for September are once again healthy. Capital growth is the focus of the total return on this stock, making the dividend payout more of an indicator than a palpable engine of appreciation at this stage. |
The Motley Fool
January 4, 2008
Timothy M. Otte |
Drugstore Sales Droop in December The three major drugstore chains, Walgreen, CVS, and Rite Aid, all report soft sales for December. |
The Motley Fool
September 26, 2007
Ryan Fuhrmann |
Foolish Forecast: Does Rite Aid Have the Right Rx? The retail pharmacy is set to release it second-quarter financial results. Investors, here is what you can expect to see. |
The Motley Fool
July 6, 2004
Steven Mallas |
Walgreen's Sunny Sales The retail pharmacy has a resplendently ruddy June, with comp sales increasing more than 10%. |
The Motley Fool
January 3, 2012
Shubh Datta |
Bright Spots for Rite Aid Better same-store sales help Rite Aid trim losses. |
The Motley Fool
November 11, 2011
Dan Caplinger |
Has Walgreen Become the Perfect Stock? Given that drug retail is a low-margin business, it's improbable that Walgreen will ever reach true perfection. But with some help, improving growth numbers is a goal that could be within reach. |
The Motley Fool
May 9, 2005
Timothy M. Otte |
Flu Means All's Well for CVS Strong comp sales and benefits from the Eckerd acquisition drive CVS to a solid first quarter. Investors, take note. |
The Motley Fool
June 28, 2005
Mike Cianciolo |
Just What Investors Prescribed With another quarter of stellar growth at Walgreen, the stock approaches its highest price ever. |
The Motley Fool
June 25, 2004
Steven Mallas |
Rite Aid in the Shadows The first quarter for Rite Aid, the pharmaceutical retailer, shows a profit, but is it time to add this stock to your portfolio? |
The Motley Fool
September 14, 2006
Ryan Fuhrmann |
Playing Defense With the Drugstore Industry Retail pharmacy August sales trends help investors discern the leader in this appealing sector. |
The Motley Fool
June 29, 2007
Ryan Fuhrmann |
Rite Aid's Recent Remedy Will increased market clout lead the drugstore operator to new highs? Investors, take note. |
The Motley Fool
December 11, 2006
Matthew Crews |
Rite Aid: Comps Mean Competition The pharmacy chain reported positive same-store results for November. Investors, take note. |
The Motley Fool
September 29, 2011
Navjot Kaur |
Should You Write Off Rite Aid? Rite Aid posts a relatively better quarter as wellness rewards the company. |
The Motley Fool
October 7, 2010 |
DRIP Portfolio Candidate: Walgreen Why this nationally known drugstore should make it into your DRIP portfolio. |
The Motley Fool
September 27, 2004
Phil Wohl |
Walgreen: Prescription for Success The leading drugstore retailer is leveraging prescription sales to produce record results. Fourth-quarter earnings grew to $0.32 per share, which was an 18% improvement over last year's $0.27. |
The Motley Fool
July 6, 2007
Timothy M. Otte |
Drugstore Sales Remain Healthy The big four drugstore chains report higher comparable sales in June. Walgreen... CVS... Rite Aid... Long's... |
The Motley Fool
October 5, 2011
Shubh Datta |
At Walgreen, It's Payback Time Walgreen buys back shares and raises its dividend. |
The Motley Fool
April 11, 2008
Ryan Fuhrmann |
Rite Aid Hasn't Fully Recovered Rite Aid needs to be nursed back to health after its acquisition of Brooks Eckerd. |
The Motley Fool
July 6, 2007
Lawrence Rothman |
Walgreen Does It Again The company continues to impress, posting positive same-store sales results month after month. At a P/E of 21, this stock isn't especially rich, given the solid performance that the company delivers. |
The Motley Fool
June 11, 2007
Mike Cianciolo |
Rite Aid's Generic Sales The drugstore chain gradually increases sales, and catches up to the big boys in one way. Investors, take note. |
The Motley Fool
September 22, 2006
Ryan Fuhrmann |
More in Store at Rite Aid? The retail pharmacy posted strong second-quarter sales, and an acquisition could help long-term results. Investors, take note. |
The Motley Fool
March 8, 2005
Seth Jayson |
Rite Aid Wretched? Value investors may be interested in Rite Aid. |
The Motley Fool
October 2, 2007
Lawrence A. Rothman |
Can the Right Prescription Heal Walgreen? Walgreen is suffering from heightened competition, expenses rising more than 11%, and the company itself predicting its challenges will probably continue into the near future. |
The Motley Fool
April 13, 2007
Ryan Fuhrmann |
Rite Aid's Right-Size Ambitions If the retail pharmacy chain can improve its net margins, reduce debt, and smoothly integrate its latest acquisition, the stock's upside would be substantial. |
The Motley Fool
September 21, 2006
Vitaliy Katsenelson |
Don't Hit the Panic Button Just Yet Wall Street plays the overreacting game; Walgreen and CVS suffer. These stocks have big tailwinds behind them. |
The Motley Fool
June 24, 2011
Shubh Datta |
A Big Question Looms for Walgreen Strong quarterly results enable the company to maintain its annual outlook, but a breakup costs dearly in the short term. |
The Motley Fool
April 9, 2007
Mike Cianciolo |
CVS: Continued Vigorous Sales The drugstore chain grows sales and itself in March. Investors, take note. |
